A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Nov 2018
At a glance
- Drugs Risankizumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms LIMMITLESS
- Sponsors AbbVie
- 21 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 03 Jul 2018 Planned number of patients changed from 2000 to 2200.
- 03 Jul 2018 Planned End Date changed from 30 Nov 2021 to 28 Dec 2021.